An innovative synthetic support for immunocytochemical assessment of cytologically indeterminate (Bethesda III) thyroid nodules.

Silvia Taccogna, Enrico Papini, Roberto Novizio, Martina D'Angelo, Luca Turrini, Agnese Persichetti, Alfredo Pontecorvi, Rinaldo Guglielmi
Author Information
  1. Silvia Taccogna: Pathology, Ospedale Regina Apostolorum, Albano Laziale, Italy.
  2. Enrico Papini: Endocrinology and Metabolism, Regina Apostolorum Hospital, Rome, Italy.
  3. Roberto Novizio: Endocrinology and Metabolism, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy.
  4. Martina D'Angelo: Pathology, Ospedale Regina Apostolorum, Albano Laziale, Italy.
  5. Luca Turrini: Pathology, Ospedale Regina Apostolorum, Albano Laziale, Italy.
  6. Agnese Persichetti: Service of Pharmacovigilance, Regina Elena National Cancer Institute, Hospital Physiotherapy Institutes (IRCCS), Rome, Italy.
  7. Alfredo Pontecorvi: Endocrinology and Metabolism, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy.
  8. Rinaldo Guglielmi: Endocrinology and Metabolism, Regina Apostolorum Hospital, Rome, Italy.

Abstract

Background: Fine needle aspiration (FNA) is the procedure of choice in the evaluation of thyroid nodules. Nodules with indeterminate cytological categories, Bethesda III and IV, pose challenges in clinical practice and are frequently submitted to diagnostic surgery. CytoFoam Core (CFCS) uses an absorbent foam device inserted into the needle hub to collect the cytological sample aspirated during FNA. Specimen is formalin-fixed and paraffin-embedded.
Aim of the study: Assessing diagnostic efficacy of CFCS, compared to traditional cytology, in re-evaluating thyroid nodules classified as Bethesda III, using post-surgical histology as reference standard.
Method: Retrospective study on 89 patients with a first indeterminate cytological report who were referred to the Department of Endocrinology of Regina Apostolorum Hospital (Albano L. Rome, Italy) for a second FNA. FNA was performed after at least one month under ultrasound guidance with a 23G needle according to the established procedure. During the second procedure, both traditional cytological (TC) smears and a single-pass CFCS specimen were obtained for each patient. On CFCS samples immunocytochemical staining for Galectin-3, HBME-1, and CK-19 was also performed. 51 patients eventually underwent surgery, and their histological diagnoses were compared to the TC and CFCS reports. Four parameters were evaluated: inadequacy rate, rate of persistent indeterminate (Bethesda III and IV) reports, rate of malignancy in persistently indeterminate nodules, and rate of cancer in lesions cytologically classified as malignant.
Results: Non-diagnostic samples were 6 (11.8%) in TC vs 3 (5.9%) in CFCS (p=0.4). Persistent indeterminate samples were 31 (60.8%) in TC vs 19 (37.2%) in CFCS (p=0.01). Rate of malignancy in persistently indeterminate nodules was 8/19 (42.1%) in CFCS vs 9/31 (29%) in TC group (p=0.3). Nine/51 (17.6%) samples were classified as benign by TC vs 21/51 (41.2%) samples by CFCS (p<0.01). All nodules resulted benign at post-surgical evaluation. Five/51 (9.8%) samples were classified as suspicious for malignancy/malignant in TC group against 8/51 (15.7%) samples in CFCS (p=0.5). Post-surgical evaluation confirmed malignancy in all these cases.
Conclusion: CFCS demonstrated greater diagnostic accuracy than TC in repeat FNA assessment of cytologically indeterminate nodules. CFCS increased the conclusive diagnosis rate and decreased the number of cytologically indeterminate cases.

Keywords

References

  1. Acta Cytol. 2016;60(5):399-405 [PMID: 27764825]
  2. Cancers (Basel). 2022 Jul 10;14(14): [PMID: 35884418]
  3. Head Neck Pathol. 2021 Mar;15(1):254-261 [PMID: 32077055]
  4. Endocr Pract. 2016 May;22(5):622-39 [PMID: 27167915]
  5. Eur Thyroid J. 2017 Sep;6(5):225-237 [PMID: 29167761]
  6. Endocrine. 2021 Jun;72(3):711-720 [PMID: 33030666]
  7. Endocrine. 2013 Oct;44(2):419-25 [PMID: 23334946]
  8. JAMA Oncol. 2019 Feb 1;5(2):204-212 [PMID: 30419129]
  9. J Clin Med. 2021 Sep 30;10(19): [PMID: 34640574]
  10. Int J Surg. 2017 May;41 Suppl 1:S60-S64 [PMID: 28506415]
  11. JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):317-22 [PMID: 24557566]
  12. South Med J. 2009 May;102(5):498-501 [PMID: 19373168]
  13. J Endocrinol Invest. 2014 Jun;37(6):593-9 [PMID: 24789536]
  14. PLoS One. 2015 Jun 26;10(6):e0130138 [PMID: 26115096]
  15. Int J Surg. 2014;12 Suppl 1:S29-34 [PMID: 24859409]
  16. Ann Surg Oncol. 2006 Mar;13(3):425-32 [PMID: 16485160]
  17. Thyroid. 2014 Jul;24(7):1115-20 [PMID: 24684285]
  18. Cancers (Basel). 2021 Nov 07;13(21): [PMID: 34771729]
  19. Diagn Pathol. 2015 Oct 26;10:196 [PMID: 26503236]
  20. Ann Ital Chir. 2010 Nov-Dec;81(6):403-10; discussion 410-1 [PMID: 21456476]
  21. Thyroid. 2016 Jan;26(1):1-133 [PMID: 26462967]
  22. J Am Soc Cytopathol. 2017 Nov - Dec;6(6):217-222 [PMID: 31043290]
  23. Mol Genet Genomic Med. 2020 Sep;8(9):e1288 [PMID: 32436637]
  24. Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):256-64 [PMID: 16082252]
  25. BMC Surg. 2014 Mar 06;14:12 [PMID: 24597765]

MeSH Term

Humans
Thyroid Nodule
Retrospective Studies
Thyroid Neoplasms
Biopsy, Fine-Needle
Cytodiagnosis

Word Cloud

Created with Highcharts 10.0.0CFCSindeterminateTCnodulessamplesFNABethesdathyroidIIIrateneedlecytologicalclassifiedcytologicallyvsp=0procedureevaluationIVdiagnosticcytologymalignancy8%surgeryCytoFoamCorecomparedtraditionalpost-surgicalpatientssecondperformedimmunocytochemicalreportspersistently352%01groupbenigncasesassessmentBackground:FineaspirationchoiceNodulescategoriesposechallengesclinicalpracticefrequentlysubmittedusesabsorbentfoamdeviceinsertedhubcollectsampleaspiratedSpecimenformalin-fixedparaffin-embeddedAimstudy:Assessingefficacyre-evaluatingusinghistologyreferencestandardMethod:Retrospectivestudy89firstreportreferredDepartmentEndocrinologyReginaApostolorumHospitalAlbanoLRomeItalyleastonemonthultrasoundguidance23Gaccordingestablishedsmearssingle-passspecimenobtainedpatientstainingGalectin-3HBME-1CK-19also51eventuallyunderwenthistologicaldiagnosesFourparametersevaluated:inadequacypersistentcancerlesionsmalignantResults:Non-diagnostic6119%4Persistent31601937Rate8/19421%9/3129%Nine/51176%21/5141p<0resultedFive/519suspiciousmalignancy/malignant8/51157%Post-surgicalconfirmedConclusion:demonstratedgreateraccuracyrepeatincreasedconclusivediagnosisdecreasednumberinnovativesyntheticsupportcategoryfineaspirateimmunoistochemestrynodule

Similar Articles

Cited By